Analyzing the Effect of ACP‐204 on the QTc Interval in Healthy Adult Participants Using Phase 1 Study Data
No meaningful increases in QTcF were observed in healthy participants after single-dose administration of ACP-204 (10-180 mg); specifically, there was no QTcF prolongation up to 180 mg.
Authors
- Jay W. Mason (ORCID: https://orcid.org/0000-0002-5713-9906)
- Bryan Dirks (ORCID: https://orcid.org/0000-0001-6472-1606)
- Mona Darwish
- Sanjeev Pathak (ORCID: https://orcid.org/0000-0003-1565-2223)
- B. Raether
- Stephanie W Stanworth
- Xiaoshu Feng
Institutions
- Acadia Pharmaceuticals (United States) (US)
- RED Consulting (Norway) (NO)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_105893
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 0.00